Oday Hamid

1.9k total citations
41 papers, 1.2k citations indexed

About

Oday Hamid is a scholar working on Oncology, Pathology and Forensic Medicine and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Oday Hamid has authored 41 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Oncology, 16 papers in Pathology and Forensic Medicine and 12 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Oday Hamid's work include Cancer Immunotherapy and Biomarkers (10 papers), Lymphoma Diagnosis and Treatment (10 papers) and Lung Cancer Treatments and Mutations (7 papers). Oday Hamid is often cited by papers focused on Cancer Immunotherapy and Biomarkers (10 papers), Lymphoma Diagnosis and Treatment (10 papers) and Lung Cancer Treatments and Mutations (7 papers). Oday Hamid collaborates with scholars based in United States, France and South Korea. Oday Hamid's co-authors include Mary Varterasian, Eric Kaldjian, Mark B. Meyer, David Mitchell, Ronald B. Natale, Román Herrera, Patricia LoRusso, Judith S. Sebolt–Leopold, John J. Rinehart and Alex A. Adjei and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Oday Hamid

41 papers receiving 1.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Oday Hamid United States	15	685	669	211	201	175	41	1.2k
Analía Azaro Spain	18	557 0.8×	569 0.9×	121 0.6×	295 1.5×	152 0.9×	56	1.1k
Alfonso Quintás‐Cardama United States	14	797 1.2×	473 0.7×	140 0.7×	242 1.2×	334 1.9×	23	1.3k
Laurence Cooke United States	19	505 0.7×	532 0.8×	213 1.0×	207 1.0×	215 1.2×	39	1.1k
Stefano Barbi Italy	19	932 1.4×	547 0.8×	297 1.4×	219 1.1×	135 0.8×	33	1.6k
Yvonne T.M. Tsang United States	18	329 0.5×	533 0.8×	161 0.8×	141 0.7×	166 0.9×	24	1.2k
Huiying Piao United States	10	442 0.6×	715 1.1×	107 0.5×	198 1.0×	98 0.6×	10	1.2k
Jens Packeisen Germany	18	557 0.8×	749 1.1×	185 0.9×	206 1.0×	87 0.5×	30	1.4k
P Bertheau France	16	800 1.2×	536 0.8×	252 1.2×	234 1.2×	173 1.0×	35	1.5k
Jeffrey P. Zwerner United States	15	288 0.4×	331 0.5×	329 1.6×	174 0.9×	219 1.3×	33	1.0k
Christopher D. Carey United States	12	593 0.9×	588 0.9×	330 1.6×	93 0.5×	343 2.0×	16	1.3k

Countries citing papers authored by Oday Hamid

Since Specialization

Citations

This map shows the geographic impact of Oday Hamid's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Oday Hamid with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Oday Hamid more than expected).

Fields of papers citing papers by Oday Hamid

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Oday Hamid. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Oday Hamid. The network helps show where Oday Hamid may publish in the future.

Co-authorship network of co-authors of Oday Hamid

This figure shows the co-authorship network connecting the top 25 collaborators of Oday Hamid. A scholar is included among the top collaborators of Oday Hamid based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Oday Hamid. Oday Hamid is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Guisier, Florian, Jaafar Bennouna, Alexander I. Spira, et al.. (2023). NeoCOAST-2: A phase 2 study of neoadjuvant durvalumab plus novel immunotherapies (IO) and chemotherapy (CT) or MEDI5752 (volrustomig) plus CT, followed by surgery and adjuvant durvalumab plus novel IO or volrustomig alone in patients with resectable non-small-cell lung cancer (NSCLC).. Journal of Clinical Oncology. 41(16_suppl). TPS8604–TPS8604. 7 indexed citations

Hamid, Omid, Benedito A. Carneiro, Thomas U. Marron, et al.. (2021). 19O Preliminary safety, antitumor activity and pharmacodynamics results of HIT-IT MEDI1191 (mRNA IL-12) in patients with advanced solid tumours and superficial lesions. Annals of Oncology. 32. S9–S9. 12 indexed citations

Marron, Thomas U., Vivek Subbiah, Omid Hamid, et al.. (2020). 1075TiP MEDI1191, a novel IL-12 mRNA therapy for intratumoral (IT) injection for advanced solid tumours. Annals of Oncology. 31. S730–S730. 1 indexed citations

Ribrag, Vincent, Seung‐Tae Lee, David A. Rizzieri, et al.. (2020). A Phase 1b Study to Evaluate the Safety and Efficacy of Durvalumab in Combination With Tremelimumab or Danvatirsen in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma. Clinical Lymphoma Myeloma & Leukemia. 21(5). 309–317.e3. 19 indexed citations

Campelo, Rosario García, Patrick M. Forde, Walter Weder, et al.. (2019). P2.04-28 NeoCOAST: Neoadjuvant Durvalumab Alone or with Novel Agents for Resectable, Early-Stage (I–IIIA) Non-Small Cell Lung Cancer. Journal of Thoracic Oncology. 14(10). S719–S719. 7 indexed citations

Palandri, Francesca, Maria R. Baer, Donald P. Quick, et al.. (2018). Phase 2 study of gandotinib (LY2784544) in patients with myeloproliferative neoplasms. Leukemia Research. 71. 82–88. 41 indexed citations

Michael, Michael, Yung‐Jue Bang, Young Suk Park, et al.. (2017). A Phase 1 Study of LY2874455, an Oral Selective pan-FGFR Inhibitor, in Patients with Advanced Cancer. Targeted Oncology. 12(4). 463–474. 68 indexed citations

Salgia, Ravi, John R. Stille, Michael McCleod, et al.. (2017). A randomized phase II study of LY2510924 and carboplatin/etoposide versus carboplatin/etoposide in extensive‐disease small cell lung cancer. Lung Cancer. 105. 7–13. 55 indexed citations

Hainsworth, John D., James A. Reeves, Joseph R. Mace, et al.. (2016). A Randomized, Open-Label Phase 2 Study of the CXCR4 Inhibitor LY2510924 in Combination with Sunitinib Versus Sunitinib Alone in Patients with Metastatic Renal Cell Carcinoma (RCC). Targeted Oncology. 11(5). 643–653. 54 indexed citations

10.

Apolo, Andrea B., J. R. Infante, Oday Hamid, et al.. (2015). 2630 Avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with locally advanced or metastatic urothelial carcinoma: A phase Ib trial. European Journal of Cancer. 51. S522–S522. 4 indexed citations

11.

Petrylak, Daniel P., Scott T. Tagawa, Manish Kohli, et al.. (2015). Interim results of a randomized phase 2 study of docetaxel with ramucirumab versus docetaxel in second-line advanced or metastatic urothelial carcinoma.. Journal of Clinical Oncology. 33(7_suppl). 295–295. 14 indexed citations

12.

Vermorken, Jan B., Lisa Licitra, Andreas Dietz, et al.. (2013). Phase II study of pemetrexed in combination with cisplatin and cetuximab in recurrent or metastatic squamous cell carcinoma of the head and neck. European Journal of Cancer. 49(13). 2877–2883. 23 indexed citations

13.

Forsyth, Cecily, David Gómez‐Almaguer, Paul Eliadis, et al.. (2013). A Multicenter, Open-Label, Noncomparative Screening Study of Enzastaurin in Adult Patients With Non-Hodgkin Lymphomas. Clinical Lymphoma Myeloma & Leukemia. 13(4). 398–403. 2 indexed citations

14.

Schwartzberg, Lee S., Róbert Hermann, Ian W. Flinn, et al.. (2012). Phase II Study of Enzastaurin in Patients with Follicular Lymphoma: Updated Final Clinical Results and Immunohistochemical Correlations. Blood. 120(21). 777–777. 4 indexed citations

15.

Voi, Maurizio, John Nemunaitis, Jessica R. Bauman, et al.. (2012). 590 Final Results of a Phase Ib Study of CUDC-101, a Multitargeted Inhibitor of EGFR, HER2, and HDAC, in Patients with Advanced Head and Neck, Gastric, Breast, Liver, and Non-small Cell Lung Cancer. European Journal of Cancer. 48. 181–181. 5 indexed citations

16.

Schmidinger, Manuela, Cezary Szczylik, Cora N. Sternberg, et al.. (2011). Dose Escalation and Pharmacokinetics Study of Enzastaurin and Sunitinib Versus Placebo and Sunitinib in Patients With Metastatic Renal Cell Carcinoma. American Journal of Clinical Oncology. 35(5). 493–497. 7 indexed citations

17.

Querfeld, Christiane, Timothy M. Kuzel, Youn H. Kim, et al.. (2011). Multicenter phase II trial of enzastaurin in patients with relapsed or refractory advanced cutaneous T-cell lymphoma. Leukemia & lymphoma. 52(8). 1474–1480. 29 indexed citations

18.

Hamid, Oday. (2004). Emerging Treatments in Oncology: Focus on Tyrosine Kinase (erbB) Receptor Inhibitors. Journal of the American Pharmacists Association. 44(1). 52–58. 22 indexed citations

19.

Seiden, Michael V., Marie Plante, Ronald K. Potkul, et al.. (2004). A phase 2, single agent study of CI-1033 administered at two doses in ovarian cancer patients who failed platinum therapy. Journal of Clinical Oncology. 22(14_suppl). 5054–5054. 14 indexed citations

20.

Hamid, Oday, Mary Varterasian, Scott Wadler, et al.. (2003). Phase II Trial of Intravenous CI-1042 in Patients With Metastatic Colorectal Cancer. Journal of Clinical Oncology. 21(8). 1498–1504. 106 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact